HETEROCYCLIC COMPOUND Russian patent published in 2023 - IPC C07D471/04 C07D487/04 A61K31/4375 A61K31/5025 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to compounds represented by the general formula (I), in which A represents

R₁ represents 1) a hydrogen atom, 2) a halogen atom, 3) a cyano group, 4) a C_1-3 alkyl group, which may be substituted by 1 to 3 halogen atoms, 5) a C_1-3 alkoxy group, 6) C_{3 -6} cycloalkyl group or 7) phenyl group; R₂ represents 1) a hydrogen atom or 2) a halogen atom; R₃ represents 1) a C_1-6 alkyl group, which may be substituted with 1 to 3 substituents selected from a C_1-3 alkoxy group, a hydroxyl group and a halogen atom, 2) a pyrazolyl group, which may be substituted with 1 to 3 substituents selected from a C_1-3 alkyl group and a halogen atom, 3) a C_3-6 cycloalkyl group, 4) an amino group disubstituted with a C_1-3 alkyl group, or 5) a phenyl group, which may be substituted by 1 to 3 atoms halogen; R₄ and R₆ represent 1) a hydrogen atom, 2) a halogen atom, 3) a C_1-3 alkyl group which may be substituted by 1 to 3 substituents selected from a) a hydroxyl group, b) a C_1-3 alkoxy group , which may be substituted by a 4-methoxyphenyl group and c) a halogen atom or 4) a C_1-3 alkoxy group, which may be substituted by 1 to 3 halogen atoms; R₅, R₇ and R₉ represent 1) a C_1-6 alkyl group, which may be substituted by 1 to 3 C_1-3 alkoxy groups, or 2) a phenyl group, which may be substituted by 1 to 3 halogen atoms; R₈ represents a C_1-3 alkyl group; and B represents 1) a phenyl group, which may be substituted by 1 to 3 substituents selected from a) a halogen atom, b) a cyano group, c) a C_1-3 alkoxy group, which may be substituted by 1 to 3 halogen atoms, and d) a triazolyl group, 2) a C_3-6 cycloalkyl group, which may be substituted with 1 to 3 substituents selected from a) a C_1-3 alkyl group, which may be substituted with 1 to 3 halogen atoms, and b) a halogen, 3) a pyridyl group, which may be substituted by 1 to 3 substituents selected from a) a halogen atom, b) a cyano group, c) a C_1-3 alkyl group, which may be substituted by 1 to 3 halogen atoms, d) C_1-3 alkoxy group, which may be substituted with 1 to 3 substituents selected from a halogen atom and a C_1-3 alkoxy group, e) pyrazolyl group, which may be substituted with 1 to 3 C_1-3 alkyl groups, f) imidazolyl group group which may be substituted with 1 to 3 C_1-3 alkyl groups, g) triazolyl group which may be substituted with 1 to 3 C_1-3 alkyl groups which may be substituted with 1 to 3 substituents selected from C_1-3 alkoxy groups and halogen atoms, h) an azetidinyl group, i) a pyrrolidonyl group, j) a tetrazolyl group, which may be substituted with 1 to 3 C_1-3 alkyl groups, k) a pyrimidinyl group and l) an oxazolyl group, 4) a pyrazolyl group, which may be substituted with 1 to 3 substituents selected from a) a C_1-3 alkyl group, which may be substituted with 1 to 3 halogen atoms, b) a C_1-3 alkoxy group, which may be substituted with 1 to 3 halogen atoms, c) a cyano group and d) a halogen atom, or 5) an imidazopyridyl group, which may be substituted by 1 to 3 halogen atoms, or pharmaceutically acceptable salts thereof.

EFFECT: production of new compounds that can be used in medicine as a preventive or therapeutic agent for the treatment of MALT1-mediated cancer.

9 cl, 4 tbl, 270 ex